Clinical Trial Results:
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IIIb TRIAL COMPARING BEVACIZUMAB THERAPY WITH OR WITHOUT ERLOTINIB AFTER COMPLETION OF CHEMOTHERAPY WITH BEVACIZUMAB FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED, RECURRENT, OR METASTATIC NON–SMALL CELL LUNG CANCER
Summary
|
|
EudraCT number |
2006-006624-19 |
Trial protocol |
GB BE BG ES IT |
Global completion date |
19 Jun 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
01 Jul 2016
|
First version publication date |
16 Jul 2015
|
Other versions |
|
Summary report(s) |
AVF3671g Redacted CSR Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.